Novimmune SA is a privately held, Swiss biopharmaceutical company. Novimmune has been granted Breakthrough therapy designation for emapalumab by the US Food and Drug Administration (FDA) and was also selected for PRIME (PRIority MEdicine) by the European Medicines Agency (EMA). Novimmune has signed two exclusive partnering agreements with Genentech, a member of the Roche Group: in 2010 on an anti-IL17 and in 2016 on an anti-TL...
Novimmune SA is a privately held, Swiss biopharmaceutical company. Novimmune has been granted Breakthrough therapy designation for emapalumab by the US Food and Drug Administration (FDA) and was also selected for PRIME (PRIority MEdicine) by the European Medicines Agency (EMA). Novimmune has signed two exclusive partnering agreements with Genentech, a member of the Roche Group: in 2010 on an anti-IL17 and in 2016 on an anti-TLR4 monoclonal antibody. Novimmune is currently performing a phase 2 study in Rheumatoid Arthritis, with this latter molecule, with results expected in the third quarter 2018.
Sponsored Ad
Upload your Marketing & Sales content on your company Virtual Booth, click HERE.